Comparison of dynamic contrast-enhancement parameters between gadobutrol and gadoterate meglumine in posttreatment glioma: a prospective intraindividual …
JE Park, JY Kim, HS Kim… - American Journal of …, 2020 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Differences in molecular properties between one-molar
and half-molar gadolinium-based contrast agents are thought to affect parameters obtained …
and half-molar gadolinium-based contrast agents are thought to affect parameters obtained …
Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model …
UI Attenberger, VM Runge, CB Jackson… - Investigative …, 2009 - journals.lww.com
Purpose: The purpose of this study is to compare the differences in contrast enhancement
using 0.1 mmol/kg body weight 1 M gadobutrol versus 2 standard gadolinium chelates, both …
using 0.1 mmol/kg body weight 1 M gadobutrol versus 2 standard gadolinium chelates, both …
The TRUTH confirmed: validation of an intraindividual comparison of gadobutrol and gadoteridol for imaging of glioblastoma using quantitative enhancement analysis
MJ Kuhn, JW Patriarche, D Patriarche… - European Radiology …, 2021 - Springer
Background Previous intraindividual comparative studies evaluating gadobutrol and
gadoteridol for contrast-enhanced magnetic resonance imaging (MRI) of brain tumours have …
gadoteridol for contrast-enhanced magnetic resonance imaging (MRI) of brain tumours have …
Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: comparison with gadoterate meglumine and gadopentetate …
UI Attenberger, VM Runge, JN Morelli… - Journal of Magnetic …, 2010 - Wiley Online Library
Purpose: To evaluate in a rat brain glioma model intraindividual tumor enhancement at 1.5 T
using gadobutrol (Gadovist), a nonionic, macrocyclic chelate currently in clinical trials in the …
using gadobutrol (Gadovist), a nonionic, macrocyclic chelate currently in clinical trials in the …
Intra-individual, randomised comparison of the MRI contrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in …
M Koenig, G Schulte-Altedorneburg, M Piontek… - European …, 2013 - Springer
Objective To prove that 1.0 M gadobutrol provides superior contrast enhancement and MRI
image characteristics of primary and secondary brain tumours compared with 0.5 M …
image characteristics of primary and secondary brain tumours compared with 0.5 M …
Signal enhancement of the dentate nucleus at unenhanced MR imaging after very high cumulative doses of the macrocyclic gadolinium-based contrast agent …
Purpose To test for measurable visual enhancement of the dentate nucleus (DN) on
unenhanced T1-weighted magnetic resonance (MR) images in a cohort of patients with a …
unenhanced T1-weighted magnetic resonance (MR) images in a cohort of patients with a …
Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of …
KR Maravilla, MP Smith, J Vymazal… - American Journal …, 2015 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Gadobutrol (Gadavist) and gadoteridol (ProHance) have
similar macrocyclic molecular structures, but gadobutrol is formulated at a 2-fold higher (1 …
similar macrocyclic molecular structures, but gadobutrol is formulated at a 2-fold higher (1 …
Evaluation of gadodiamide versus gadobutrol for contrast-enhanced MR imaging in a rat brain glioma model at 1.5 and 3 T
JN Morelli, VM Runge, L Vu, AT Loynachan… - Investigative …, 2010 - journals.lww.com
Purpose: To compare equivalently-dosed (0.1 mmol/kg) gadobutrol (Gadovist) and
gadodiamide (Omniscan) in a rat brain glioma model with respect to lesion signal-to-noise …
gadodiamide (Omniscan) in a rat brain glioma model with respect to lesion signal-to-noise …
Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0 M) and gadoterate meglumine (0.5 M) …
N Anzalone, T Scarabino, C Venturi, C Cristaudo… - European Journal of …, 2013 - Elsevier
OBJECTIVE: Two macrocyclic extracellular contrast agents, one-molar neutral gadobutrol
and ionic gadoterate meglumine, were compared to determine the overall preference for …
and ionic gadoterate meglumine, were compared to determine the overall preference for …
Brain relaxometry after macrocyclic Gd-based contrast agent
A Müller, A Jurcoane, B Mädler, P Ditter, H Schild… - Clinical …, 2017 - Springer
Purpose To assess if ratios of T1-weighted (T1w) signal intensity (SI) and quantitative T1
relaxometry (qT1) change on serial administration of macrocyclic gadobutrol. Methods A …
relaxometry (qT1) change on serial administration of macrocyclic gadobutrol. Methods A …
Related searches
- contrast enhancement gadoterate meglumine
- clinical setting gadoterate meglumine
- body weight gadoterate meglumine
- contrast agent signal enhancement
- contrast agent brain relaxometry
- contrast agent cumulative doses
- contrast agent dentate nucleus
- high relaxivity contrast agents
- intraindividual comparison enhancement analysis
- intraindividual comparison imaging of glioblastoma
- high stability contrast agents
- high concentration contrast agents
